JPRN-jRCT2080220419UnknownPhase 1
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- AstraZeneca
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 75age old (—)
- Sex
- All
Inclusion Criteria
- •Ages Eligible for Study: 20 Years - 75 Years
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- advanced solid tumors
- •- life expectancy is 12 weeks or longer
Exclusion Criteria
- •- patient with uncontrolled brain metastases
- •- patient with inappropriate laboratory test values
- •- patient with poorly controlled hypertension
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)EUCTR2017-001684-21-FReuroVia, Inc.25
Recruiting
Phase 2
Study of Subretinally Injected AAVB-081 in Patients with Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa2024-518489-29-00Aavantgarde Bio S.r.l.9
Active, not recruiting
Not Applicable
A Phase I/IIa Open-label Dose Escalation Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283 in Patients with Intermediate or High-Risk Myelofibrosis.MedDRA version: 9.1Level: LLTClassification code 10028537Term: MyelofibrosisMyelofibrosisEUCTR2007-005299-15-GBAstex Therapeutics Ltd
Not yet recruiting
Phase 2
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)NUT Midline Carcinoma and other solid tumors10027655NL-OMON43804GlaxoSmithKline10
Unknown
Phase 1
A Phase I, Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080220492AstraZeneca